Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T10745 |
CDK9-IN-7
|
CDK | Cell Cycle/Checkpoint |
CDK9-IN-7 (compound 21e) 是一种高效选择性的,具有口服活性的 CDK9/cyclin T 抑制剂 (IC50=11 nM),与抑制其他 CDK 相比更有效 (CDK4/cyclinD=148 nM; CDK6/cyclinD=145 nM)。CDK9-IN-7 具有抗癌活性并没有明显的毒性。CDK9-IN-7 诱导非小细胞肺癌 (NSCLC) 细胞凋亡,在 G2 期阻滞细胞周期,并具有抑制非小细胞肺癌干细胞特性。 | |||
T40353 |
CDK7/9-IN-1
CDK7/9-IN-1 |
||
CDK7/9-IN-1 is a specific inhibitor of cyclin-dependent kinases 7/9 (CDK7/9). It specifically targets CDK7, while also displaying inhibitory activity against CDK9. CDK7/9-IN-1 demonstrates excellent inhibitory potency against CDK7, with IC50 values of 0.0656 μM and 0.00574 μM without pre-incubation and after 3 hours pre-incubation, respectively. Furthermore, CDK7/9-IN-1 inhibits CDK9 with an IC50 of 2.14 μM after 3 hours pre-incubation. Its application in cancer research makes it valuable for su... | |||
T62791 | CDK7-IN-16 | ||
CDK7-IN-16 (compound 9) 是一种 CDK 7 的有效抑制剂 (IC50: 1-10 nM)。CDK7-IN-16 能够用于研究抗癌,特别是转录异常的癌症。 | |||
T72951 |
CDK4/6-IN-14
|
||
CDK4/6-IN-14 是一种有效且高度选择性的 CDK4和 CDK6(CDK) 抑制剂,IC50分别为 10 nM 和 16 nM。CDK4/6-IN-14 的选择性是 CDK1、2、7 和 9 的 60 多倍,并且在其他 205 种激酶中表现出高选择性。 |